Health
J&J Quarterly Earnings Beat Expectations, Shows Progress on Talc Liabilities
- Cancer drug Darzalex drives 5% gain in pharmaceutical sales
- Company makes progress in addressing talc-related liabilities
This article is for subscribers only.
Johnson & Johnson reported stronger-than-expected third-quarter earnings, driven by surging sales of the cancer medicine Darzalex.
The company also lowered its full-year guidance to account for a medical device acquisition, according to a statement Tuesday.